Evidence map›Paper›PMID 42012198›Full record

ArticleMicrobiology spectrum2026

Compound Biejia-Ruangan tablets activate the STING-TBK1 pathway to alleviate hepatic fibrosis in alveolar echinococcosis.

Yuyu Ma, Hui Zhao, Yumei Liu, Menggen Meng, Jiahui Chen, Yuqin Sun, Bin Fan, Xuan Zhou, Fengmin Tian, Xiumin Ma and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuyu Ma *State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.
Hui Zhao *Medical Testing Center, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Yumei Liu *Medical Testing Center, Xinjiang Medical University Affiliated Traditional Chinese Medicine Hospital, Urumqi, Xinjiang, China.
Menggen Meng *State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.
Jiahui ChenState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.
Yuqin SunState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.
Bin FanBasic Medical College of Xinjiang Medical University, Urumqi, Xinjiang, China.
Xuan ZhouState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.
Fengmin TianState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.
Xiumin MaState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.ORCID 0000-0001-8011-7513
Liang WangState Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Laboratory Center, Tumor Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang, China.ORCID 0009-0007-3697-3970

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alveolar echinococcosis (AE) is a lethal parasitic disease that leads to progressive liver fibrosis, a process characterized by the dominance of M2 macrophages in advanced stages. While the compound Biejia-Ruangan tablet (CBRT) has demonstrated efficacy in reversing hepatic fibrosis, its underlying mechanisms in the context of AE-induced fibrosis are not fully understood. This study aimed to investigate the therapeutic potential of CBRT against AE-induced liver fibrosis and to elucidate its mechanisms of action. Serum levels of liver fibrosis markers and cytokines were measured by ELISA. Liver histopathology and collagen deposition were assessed using H&E and Masson's trichrome staining. Apoptosis in GHA1 hepatocytes was evaluated by flow cytometry. Macrophage migration was analyzed via scratch and Transwell invasion assays. The involvement of the STING-TBK1 signaling pathway was examined through western blotting (WB), immunohistochemistry (IHC), immunofluorescence (IF), and quantitative real-time PCR (qRT-PCR). Livers from IMPORTANCE: This study demonstrates that compound Biejia-Ruangan tablet (CBRT) alleviates

Indexed as

Echinococcosis, HepaticLiver CirrhosisMembrane ProteinsProtein Serine-Threonine KinasesAnimalsApoptosisCell LinecGAS-STING Signaling PathwayDisease Models, AnimalEchinococcosisEchinococcus multilocularisHepatic Stellate CellsHepatocytesHumansLiverMacrophagesMembrane ProteinsProtein Serine-Threonine KinasesSting1 protein, mouseSTING ProteinTabletsTbk1 protein, mousecompound Biejia-Ruangan tablethepatic fibrosisSTING-TBK1 signaling pathway

Identifiers

PMID42012198
PMCPMC13228014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.